

1 **Serological surveillance reveals a high exposure to SARS-**
2 **CoV-2 and altered immune response among COVID-19**
3 **unvaccinated Cameroonian individuals**

4 **Arlette Flore Mogue Mougou Soubgui^{1,2}, Wilfred Steve Ndeme Mboussi^{1,2}, Loick Pradel Kojom**
5 **Foko^{2,3*}, Eliséé Libert Embolo Enyegue⁴, Martin Luther Koanga Mogtomo^{1,2*}**

6 ¹ Department of Biochemistry, Faculty of Science, The University of Douala, Cameroon

7 ² Centre de Recherche et d'Expertise en Biologie, Douala, Cameroon

8 ³ Department of Animal Biology, Faculty of Science, The University of Douala, Cameroon

9 ⁴ Center for Research on Health and Priority Diseases, Ministry of Scientific Research and
10 Innovation, Yaounde, Centre Region, Cameroon

11 **Short title: SARS-CoV-2 seroprevalence and immune response in Cameroon**

12 *Corresponding authors

13 koanga@yahoo.com (MLKM) and kojomloick@gmail.com (LPKF)

14

15 **ORCID Authors**

16 Arlette Flore Mogue Mougou Soubgui (<https://orcid.org/0000-0001-8229-9533>)

17 Loick Pradel Kojom Foko (<https://orcid.org/0000-0002-4286-147X>)

18 Eliséé Libert Embolo Enyegue (<https://orcid.org/0000-0002-5802-6858>)

19 Martin Luther Koanga Mogtomo (<https://orcid.org/0000-0003-4323-9428>)

20 **Abstract**

21 **Background**

22 Surveillance of COVID-19/SARS-CoV-2 dynamics is crucial to understanding natural history
23 and providing insights into the population's exposure risk and specific susceptibilities. This
24 study investigated the seroprevalence of SARS-CoV-2 antibodies, its predictors, and
25 immunological status among unvaccinated patients in Cameroon.

26 **Materials and Methods**

27 A multicentre cross-sectional study was conducted between January and September 2022 in
28 the town of Douala. Patients were consecutively recruited, and data of interest were
29 collected using a questionnaire. Blood samples were collected to determine Immunoglobulin
30 titres (IgM and IgG) by ALFA, CD4+ cells by flow cytometry, and interferon gamma (IFN- γ)
31 and interleukin-6 (IL-6) by ELISA.

32 **Results**

33 A total of 342 patients aged 41.5 ± 13.9 years were included. Most participants (75.8%) were
34 asymptomatic. The overall prevalence of IgM and IgG was 49.1% and 88.9%, respectively.
35 Ageusia and anosmia have displayed the highest positive predictive values (90.9% and
36 82.4%) and specificity (98.9% and 98.3%). The predictors of IgM seropositivity were being
37 aged 60 – 70 years (aOR = 0.54, $p = 0.02$) and ageusia (aOR = 9.31, $p = 0.01$), whereas those
38 of IgG seropositivity included health facility (aOR = 0.23, $p = 0.02$) and ageusia (aOR = 0.21, p
39 = 0.04). CD4+, IFN- γ , and IL-6 were impaired in seropositive individuals, with a confounding
40 role of socio-demographic factors or comorbidities.

41 **Conclusion**

42 Although the WHO declared the end of COVID-19 as a public health emergency, the findings
43 of this study indicate the need for continuous surveillance to adequately control the disease
44 in Cameroon.

45 **Keywords**

46 SARS-CoV-2; seroprevalence; predictors; immunological status; unvaccinated people;

47 Cameroon

48

49 **Introduction**

50 A large number of pathogens have emerged and re-emerged in the last two decades and
51 negatively impact the health, wellbeing, and economy of the world's populations. Several
52 factors, greatly due to anthropic activities and climate change, have been indexed as the
53 main causes of the appearance and/or resurgence of several infectious diseases [1]. The
54 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive sense single-
55 stranded ribonucleic acid virus, responsible for coronavirus disease 2019 (COVID-19) [2], is
56 the latest example of this catastrophic scenario of emerging pathogens. Since its initial
57 emergence in Wuhan, Hubei region, China, in December 2019, an estimated ~677 million
58 cases and ~6.9 million deaths were attributed to SARS-CoV-2 as of 10 March 2023
59 (<https://coronavirus.jhu.edu/map.html>).

60 Methods relying on molecular detection of the viral genome, i.e., retrotranscriptase
61 quantitative polymerase chain reaction (RT-qPCR), are gold standards for diagnostic and

62 surveillance purposes. In developed areas, RT-qPCR is highly operational at the national
63 level, but it is not the case in developing regions such as sub-Saharan Africa, where this
64 technique is not affordable for most health facilities, especially those from remote and/or
65 hard-to-reach population areas. In addition, RT-qPCR-based estimates do not reflect the real
66 circulation and spread of SARS-CoV-2 in populations, as this technique can give false-
67 negative results especially at initial testing (i.e., at the first healthcare encounter) [3], and is
68 commonly recommended for individuals presenting COVID-19-like respiratory signs and
69 symptoms [4]. In this context, it is crucial to develop alternative methods to overcome these
70 main limitations of molecular techniques.

71 Serological testing for SARS-CoV-2 infection has become an important pillar in surveillance
72 efforts. Seroprevalence studies quantify the number of individuals who have developed an
73 immune response, i.e. antibodies, against a pathogen. The studies rely of the detection of
74 immunoglobulins (e.g., IgG, IgM) produced followed infection with SARS-CoV-2. The
75 production of these anti-SARS-CoV-2 antibodies corresponds to several phases of the natural
76 course of viral infection. IgM are produced early in the humoral immune response against
77 SARS-CoV-2 infection, and then they are switched to IgG, which has a higher affinity for viral
78 antigens than IgM [5,6]. Not only can the large scale implementation of highly sensitive and
79 specific serological tests help to know the real picture of spread of SARS-CoV-2 by tracking
80 asymptomatic carriers of the virus who are missed by traditional surveillance systems, but
81 these can also evaluate the effectiveness of control measures [5].

82 There is a lack of serological studies in African settings in the context of boosting efforts to
83 continuous surveillance and control the disease. We therefore conducted a serological study
84 to determine the prevalence and determinants of anti- SARS-CoV-2 antibodies among

85 unvaccinated individuals living in the town of Douala, Cameroon. In addition, we evaluated
86 variations in markers of immune responses (interferon, lymphocytes, and interleukins).

87 **Materials and Methods**

88 **Study design**

89 This cross-sectional study was conducted between January, 1st and September, 31st, 2022 in
90 seven health facilities in the town of Douala, Littoral Region, Cameroon. The study sites
91 included Bangue district hospital, Boko health care centre, Bonassama district hospital, Cité
92 des Palmiers district hospital, Deido district hospital, New Bell district hospital, and Nylon
93 district hospital. Douala is the economic capital and most populated town of Cameroon.
94 Populations living in this town are highly diverse, with the predominance of three ethnic
95 groups (*Duala, Bamileke, and Bassa*) [7]. A questionnaire was administered to each
96 participant to collect sociodemographic, anthropometric, and clinical information, while
97 blood samples were collected to measure immune response parameters, respectively. A
98 summary of the main activities conducted during the study is summarized in Fig 1.

99

100 **Fig 1. Flow diagram of the study.** COVID-19: Coronavirus disease 2019, Ig: Immunoglobulin,
101 CD: Cluster of differentiation, IFN- γ : Interferon gamma, IL-6: Interleukin 6

102

103 **Eligibility criteria**

104 We included all Cameroonian patients of both sexes, aged > 18 years old, settled in Douala,
105 and having signed an informed consent form. In contrast, we excluded from this study: i)

106 foreigners, ii) patients who were not willing to participate, iii) those who refused to sign an
107 informed consent form, iv) those admitted to intensive care units; and v) those for whom
108 blood collection was impossible.

109 **Sample size calculation**

110 Participants were recruited consecutively using random sampling to limit selection and
111 information biases. The sample size was determined using Lorentz's formula $n = [Z^2 \times p \times (1 -$
112 $p)]/d^2$, where n = the required sample size, Z = statistics for the desired confidence interval (Z
113 = 1.96 for 95% confidence level), d = accepted margin of error ($d = 5\%$), and p =
114 seroprevalence of SARS-CoV-2 antibodies in Africa (19.5%) [8]. The required sample size for
115 this study was estimated as $n = 241$ participants.

116 **Data collection**

117 About three millilitres of whole blood were collected from each patient by venepuncture in
118 properly labelled tubes. A structured pre-tested questionnaire was used to collect data of
119 interest, which consisted of sociodemographic information (age, gender, educational level,
120 occupation, and marital status), anthropometric parameters (weight, height, body mass
121 index), and clinical information (clinical signs and symptoms, COVID-19 vaccination uptake,
122 and presence of comorbidities such as diabetes and hypertension).

123 **Determination of immune response parameters**

124 Venous blood samples were used to determine levels of CD4+, immunoglobulins M and G
125 (IgM and IgG), interferon gamma (IFN- γ) and interleukin 6 (IL-6). The blood level of CD4+ was
126 determined using a Sysmex XF-1600™ Flow Cytometer (<https://www.sysmex-ap.com>). Blood

127 samples were centrifuged, and the resulting supernatant (serum) was used to determine
128 levels of immunoglobulins, IFN- γ , and IL-6. All serum samples were tested for anti-SARS-CoV-
129 2 virus IgG and IgM antibodies using a VIDAS[®] SARS-COV-2 IgG/IgM kit (Reference 423833)
130 (www.biomerieux-usa.com) which is an automated assay based on the enzyme-linked
131 immunofluorescent assay (ALFA) technique. Samples were considered positive for both IgG
132 and IgM when the test values were greater than 1. IFN- γ and IL-6 were measured by
133 sandwich enzyme-linked immunosorbent assay (ELISA). Spectrophotometric measurements
134 of IFN- γ and IL-6 were done at wavelength 450 nm. All experiments were performed in
135 duplicate and in accordance with the manufacturer's instructions.

136 **Ethical statements**

137 An ethical authorization was issued by the institutional review board of the University of
138 Douala (N^o 2945 CEI-UDo/12/2021/T), Littoral Health Regional Delegation (N^o 0038/
139 AAR/MINSANTE/DRSPL/BCASS), and Douala Laquintinie Hospital (N^o
140 08179/AR/MINSANTE/DHL) (S1 Fig). The study was explained to participants in the two
141 official languages they understood best (French or English), and their questions were
142 answered. Patients were informed about the objectives, advantages, and risks of the study,
143 and then asked to sign a written informed consent form before their enrolment. Participants
144 were informed that the study was strictly voluntary, and they were free to decline answering
145 any question or totally withdraw if they so wished at any time.

146 **Statistical analysis**

147 Data were presented as percentages with 95% confidence intervals (95%CI) for categorical
148 variables, and mean \pm standard deviation (SD) or standard error (SE) for continuous

149 variables. The percentages were compared using Fisher's exact and Pearson's independence
150 chi-square (χ^2) tests. Continuous variables were tested for normal distribution using the
151 Kolmogorov-Smirnov test to decide whether parametric and non-parametric statistical tests
152 were suitable for comparative analyses (S2 Fig). Parametric tests including one-way analysis
153 of variance (ANOVA), post-hoc Duncan's test, unpaired samples Student t-test and Pearson
154 correlation were used for variables following a Gaussian distribution. The non-parametric
155 versions of these tests (i.e., Kruskal-Wallis test, Mann-Whitney test and Spearman
156 correlation) were used for variables that failed to reach a Gaussian distribution. Univariate
157 and multivariate logit models were used to identify determinants of SARS-CoV-2 antibodies.
158 The association between independent variables and SARS-CoV-2 antibodies was quantified
159 by crude and adjusted odds ratios (cOR and aOR), 95% CIs, and level of statistical significance.
160 The independent variables included in the logit model were health facility, gender, age,
161 marital status, educational level, occupation, comorbidities, clinical signs and symptoms,
162 blood group, COVID-19 vaccination uptake, history of past COVID-19, and history of recent
163 infection). Based on the findings of the univariate analysis, variables that were significant in
164 the univariate analysis were used to build the multivariate logistic model. A two-tailed p -
165 value < 0.05 was considered statistically significant. No imputation was performed for
166 missing values. GraphPad version 5.03 for Windows (GraphPad PRISM, San Diego, Inc.,
167 California, USA), SPSS version 16 for Windows (SPSS IBM, Inc., Chicago, Illinois, USA), and
168 StatView version 5.0 for Windows (SAS Institute, Chicago, Illinois, USA) software were used
169 to perform statistical analyses. All analyses were performed as recommended in the SAMPL
170 Guidelines [9].

171

172 Results

173 SARS-CoV-2 antibody response by COVID-19 status

174 Unvaccinated patients accounted for 81.4% of the patients (Fig 2a). The serum titres of IgM
175 were significantly higher in unvaccinated patients compared to fully vaccinated patients ($p =$
176 0.03) (Fig 2b), but no significant difference was found for IgG (Fig 2c). Unvaccinated patients
177 were analysed in the next sections as per the study objectives.

178

179 **Fig 2. Proportion of unvaccinated patients (a), and serum levels of IgM (b) and IgG (c) by**
180 **COVID-19 vaccination status.** The one-way analysis of variance (ANOVA) and Duncan's post-
181 hoc tests were used to make pairwise comparisons between groups. In Figures 2 b and 2c,
182 only statistically significant comparisons were showed on the graphs. *Statistically significant
183 at p -value < 0.05

184

185 Characteristics of the unvaccinated participants

186 Of the 342 participants, females and elderly people accounted for 47.7% and 13.2%,
187 respectively. The mean age \pm SD of the study population was 41.5 ± 13.9 years. Obesity was
188 the main comorbidity (24.6%) found in participants. The bulk of participants (75.8%) were
189 asymptomatic, even though a few individuals presented clinical symptoms represented
190 mainly by cough (12.1%), severe fatigue (10.9%), and headache (9%) (Table 1).

191

192

193 **Table 1. Details of the patients included in the study.**

Variables	<i>n</i> (%)
Sociodemographic data (N = 342)	
Females, <i>n</i> (%)	163 (47.7%)
Age ≥ 60 years, <i>n</i> (%)	45 (13.2%)
Mean age ± SD (years)	41.5 ± 13.9
Married, <i>n</i> (%)	179 (52.3%)
University level, <i>n</i> (%)	208 (60.8%)
Comorbidities (N = 342)	
Obesity, <i>n</i> (%)	84 (24.6%)
Hypertension, <i>n</i> (%)	37 (10.8%)
Diabetes, <i>n</i> (%)	21 (6.1%)
Asthma, <i>n</i> (%)	11 (3.2%)
Heart failure, <i>n</i> (%)	8 (2.3%)
Human immunodeficiency infection, <i>n</i> (%)	5 (1.5%)
Cancer, <i>n</i> (%)	2 (0.6%)
Stroke, <i>n</i> (%)	2 (0.6%)
Coronary heart disease, <i>n</i> (%)	1 (0.3%)
Renal impairment, <i>n</i> (%)	0 (0.0%)
Clinical signs/symptoms (N = 342)	
Asymptomatic, <i>n</i> (%)	258 (75.8%)
Cough, <i>n</i> (%)	49 (14.3%)
Severe fatigue, <i>n</i> (%)	40 (11.7%)

Headache, <i>n</i> (%)	35 (10.2%)
Fever, <i>n</i> (%)	32 (9.4%)
Respiratory difficulties, <i>n</i> (%)	27 (7.9%)
Sore throat, <i>n</i> (%)	27 (7.9%)
Running nose, <i>n</i> (%)	23 (6.7%)
Ageusia, <i>n</i> (%)	22 (6.4%)
Anosmia, <i>n</i> (%)	17 (4.9%)
Irritability/Confusion, <i>n</i> (%)	9 (2.6%)
Loss of appetite, <i>n</i> (%)	5 (1.5%)
Nausea, <i>n</i> (%)	4 (1.2%)
Diarrhoea, <i>n</i> (%)	4 (1.2%)
Vomiting, <i>n</i> (%)	2 (0.6%)

194

195 **Overall prevalence of SARS–CoV–2 antibodies among COVID-19**

196 **unvaccinated patients**

197 A high proportion of patients were positive for both anti-SARS-CoV-2 antibodies, with an
 198 overall prevalence of 49.1% ($n = 168$, 95%CI 43.9 – 54.4%) for IgM, and 88.9% ($n = 304$,
 199 95%CI 85.1 – 91.8%) for IgG. By combining the two antibodies, the prevalence was 96.8% (n
 200 = 331, 95%CI 94.3 – 98.2%). A statistically significant geographical variation in the prevalence
 201 of IgG, with the highest prevalence rate in patients from the Boko hospital (100%) and the
 202 lowest rate in patients from the Deido hospital (63.6%) (Fig 3 and S3 Table). No significant

203 difference was found between the prevalence of IgM ($p = 0.51$) or Ig G + IgM ($p = 0.22$) after
204 stratification by geographical area (Fig 3 and S3 Table).

205

206 **Fig 3. Prevalence of SARS–CoV–2 antibodies by study sites.** The map was generated using
207 ArcGIS v8.1 software (Esri, Redlands, CA, USA) and GraphPad version 5.03 for Windows
208 (GraphPad PRISM, San Diego, Inc., California, USA). The pie charts depict the prevalence of
209 patients positive for IgM (black section), IgG (pink section) and IgG + IgM (purple section).

210 *For Deido district hospital, the sample collection site was located in Bonamoussadi

211 neighbourhood. ** For Bangue district hospital, the sample collection site was located in

212 Akwa neighbourhood

213

214 **Seroprevalence profile by clinical status among COVID-19**

215 **unvaccinated patients**

216 The prevalence of IgG and/or IgM by clinical symptoms is depicted in Figure 4. Overall, the
217 presence of IgM was more frequently seen among symptomatic patients. The trend was
218 inverted regarding IgG antibodies, but there was no statistically significant difference for the
219 concomitant presence of IgM + IgG. For instance, higher proportions of IgM+ patients were
220 found in those with fever (71.9% vs 46.8%, $p = 0.0008$), ageusia (90.9% vs 46.3%, $p < 0.0001$),
221 and anosmia (82.4% vs 47.4%, $p = 0.005$) (Fig 4 and S4 Table). Moreover, ageusia and
222 anosmia were the COVID-19 symptoms that displayed the highest positive predictive values
223 (90.9% and 82.4%) and specificity (98.9% and 98.3%) (S5 Table).

224

225 **Fig 4. Prevalence of SARS–CoV–2 antibodies by main clinical symptoms.** Ig:
226 Immunoglobulin, n.s: Not significant, SARS–CoV–2: Severe acute respiratory syndrome
227 coronavirus 2. Each bar represents the proportion of patients seropositive with respect to
228 clinical symptoms. Only symptoms with occurrence > 15 were included in the analysis.
229 Pearson’s independence chi-square and Fisher’s exact tests were used to compare
230 percentages. *Statistically significant at * p -value < 0.05, ** p -value < 0.01, and *** p -value <
231 0.0001

232

233 **Seroprevalence by demographical information and comorbidities** 234 **among COVID-19 unvaccinated patients**

235 The variation of seroprevalence by demographical details and comorbidities is summarized
236 in S6 Table. The prevalence of IgM was significantly higher in patients aged below 30 years
237 (59.8%) and then decreased, with the lowest rates seen in patients 70 years (27.3%). The
238 proportion of patients with IgG antibodies was higher in non-asthmatic patients as compared
239 to their asthmatic counterparts (89.7% vs 63.6%, $p = 0.02$). No significant association was
240 found between the presence of IgM and IgG antibodies, demographical characteristics, or
241 comorbidities (S6 Table).

242 **Determinants of SARS-CoV-2 antibody response among COVID-19** 243 **unvaccinated patients**

244 Based on univariate logistic regression analysis, a total of four factors associated with the
245 presence of IgM antibodies were identified: age, marital status, frequent healthcare seeking,

246 and occupation. The risk of the presence of IgM was reduced by 63% in patients aged 60 – 70
 247 years (cOR = 0.37, 95%CI 0.16 – 0.84, $p = 0.01$) compared to those aged < 30 years. Similarly,
 248 the risk of IgM was reduced by 75% (cOR = 0.25, 95%CI 0.07 – 0.94, $p = 0.04$) in divorced or
 249 widowed patients, and by 51% (cOR = 0.49, 95%CI 0.25 – 0.98, $p = 0.04$) in patients working
 250 in the formal sector compared to singles and students, respectively. In contrast, the odds of
 251 being positive for IgM were nearly two-fold higher in frequently seeking care individuals
 252 (cOR = 1.71, 95%CI 1.09 – 2.66, $p = 0.01$) (Table 2). Regarding IgG, two factors were identified
 253 namely health facility and asthma. The risk of being positive for IgG was reduced in patients
 254 from the Deido hospital (cOR = 0.16, 95%CI 0.05 – 0.48, $p = 0.002$) compared to those
 255 recruited at the Bangue hospital. Likewise, the odds of being positive for IgG were reduced in
 256 asthmatic patients (cOR = 0.20, 95%CI 0.06 – 0.72, $p = 0.01$).

257 **Table 2. Univariate logistic regression between SARS-CoV-2 antibodies, demographical**
 258 **information, clinical data and comorbidities among COVID-19 unvaccinated patients.**

Variables	Categories	IgM		IgG	
		cOR (95%CI)	p	cOR (95%CI)	p
Sociodemographic characteristics					
Health facility	Bangue	1		1	
	Boko	0.73 (0.27 - 1.95)	0.53	0.71 (0.15 - 2.58)	0.97
	Bonassama	1.38 (0.73 - 2.60)	0.31	0.85 (0.29 - 2.51)	0.76
	Cité des Palmiers	1.10 (0.59 - 2.05)	0.76	0.73 (0.26 - 2.06)	0.55
	Deido	0.83 (0.33 - 2.09)	0.69	0.16 (0.05 - 0.48)	0.001*
	New-Bell	0.69 (0.33 - 1.46)	0.34	1.09 (0.28 - 4.26)	0.96
	Nylon	0.61 (0.26 - 1.41)	0.25	0.44 (0.13 - 1.42)	0.17

Age (years old)	< 30	1		1	
	[30 - 40[0.57 (0.31 - 1.04)	0.06	1.39 (0.56 - 3.47)	0.47
	[40 - 50[0.59 (0.31 - 1.15)	0.06	1.83 (0.60 - 5.56)	0.28
	[50 - 60[0.82 (0.41 - 1.66)	0.58	1.43 (0.46 - 4.37)	0.53
	[60 - 70[0.37 (0.16 - 0.84)	0.01*	0.90 (0.29 - 2.82)	0.85
	70+	0.25 (0.06 - 1.02)	0.05	0.70 (0.13 - 3.66)	0.66
Gender	Females	1		1	
	Males	0.76 (0.49 - 1.16)	0.19	0.69 (0.35 - 1.37)	0.28
Marital status	Single	1		1	
	Married	0.72 (0.46 - 1.11)	0.12	0.54 (0.26 - 1.11)	0.09
	Divorced/Widow	0.25 (0.07 - 0.94)	0.04*	1.04 (0.12 - 8.73)	0.96
Educational level	None/Primary	1		1	
	Secondary	0.93 (0.37 - 2.32)	0.88	0.83 (0.17 - 4.01)	0.82
	University	0.98 (0.41 - 2.36)	0.97	0.77 (0.17 - 3.49)	0.73
Occupation	Student	1		1	
	Formal sector	0.49 (0.25 - 0.98)	0.04*	0.63 (0.18 - 2.17)	0.45
	Informal sector	0.59 (0.27 - 1.31)	0.19	0.53 (0.13 - 2.07)	0.35
Clinical characteristics					
Obesity	No	1		1	
	Yes	0.72 (0.44 - 1.18)	0.19	0.90 (0.42 - 1.94)	0.78
Diabetes	No	1		1	
	Yes	0.49 (0.19 - 1.26)	0.14	0.73 (0.21 - 2.62)	0.63
Hypertension	No	1		1	

	Yes	0.87 (0.44 - 1.72)	0.68	0.61 (0.23 - 1.56)	0.29
Heart failure	No	1		1	
	Yes	0.34 (0.07 - 1.69)	0.19	-	-
HIV	No	1		1	
	Yes	0.69 (0.11 - 4.16)	0.68	0.49 (0.05 - 4.53)	0.53
Asthma	No	1		1	
	Yes	1.85 (0.53 - 6.43)	0.33	0.20 (0.06 - 0.72)	0.01*
History of COVID-19	No	1		1	
	Yes	0.79 (0.41 - 1.52)	0.48	5.61 (0.75 - 42.01)	0.09
Blood group	A	1		1	
	AB	0.82 (0.28 - 2.45)	0.72	1.04 (0.12 - 9.28)	0.97
	B	0.63 (0.33 - 1.22)	0.17	1.07 (0.29 - 3.98)	0.91
	O	0.98 (0.58 - 1.63)	0.93	0.41 (0.16 - 1.04)	0.06
Frequently care seeking	No	1		1	
	Yes	1.71 (1.09 - 2.66)	0.01*	0.79 (0.39 - 1.59)	0.51

259 95%CI: Confidence interval at 95%, COVID-19: Coronavirus disease 2019, cOR: Crude odds ratio, aOR:

260 Adjusted odds ratio, HIV: Human immunodeficiency virus infection, Ig: Immunoglobulin, SARS-CoV-

261 2: Severe acute respiratory syndrome coronavirus 2

262 Univariate logistic regression analysis was performed to quantify the association between presence

263 of anti-SARS-CoV-2 antibodies (IgG and IgM), demographical information, clinical data and

264 comorbidities

265 *Statistically significant at p -value < 0.05

266

267 It was noted that the risk of being positive for IgM was increased but decreased for IgG in
 268 symptomatic patients, especially for those with fever, pain, respiratory difficulties,
 269 headache, severe fatigue, ageusia, or anosmia (Table 3). For instance, the IgM-related risk
 270 was increased in patients with fever (cOR = 2.91, 95%CI 1.30 – 6.49, $p = 0.009$), ageusia (cOR
 271 = 11.62, 95%CI 2.67 – 50.56, $p = 0.0001$), and anosmia (cOR = 5.18, 95%CI 1.46 – 18.38, $p =$
 272 0.01). Conversely, the risk of being positive for IgG was reduced by 85% (cOR = 0.15, 95%CI
 273 0.07 – 0.35, $p < 0.0001$), 88% (cOR = 0.12, 95%CI 0.05 – 0.29, $p < 0.0001$), and 85% (cOR =
 274 0.15, 95%CI 0.05 – 0.42, $p = 0.0003$) in patients with fever, ageusia, and anosmia,
 275 respectively (Table 3).

276 **Table 3. Univariate logistic regression analysis between presence of anti-SARS-CoV-2**
 277 **antibodies and clinical signs/symptoms among COVID-19 unvaccinated patients.**

Variables	Categories	IgM		IgG	
		cOR (95%CI)	p	cOR (95%CI)	p
Cough	No	1		1	
	Yes	1.61 (0.87 - 2.97)	0.13	0.17 (0.08 - 0.35)	< 0.0001*
Fever	No	1		1	
	Yes	2.91 (1.30 - 6.49)	0.009*	0.15 (0.07 - 0.35)	< 0.0001*
Sore throat	No	1		1	
	Yes	1.85 (0.82 - 4.16)	0.14	0.51 (0.18 - 1.45)	0.21
Pain	No	1		1	
	Yes	2.86 (1.16 - 7.05)	0.02*	0.22 (0.09 - 0.56)	0.001*
Running nose	No	1		1	
	Yes	2.51 (1.01 - 6.27)	0.04*	0.25 (0.09 - 0.64)	0.004*

Respiratory difficulties	No	1		1	
	Yes	2.65 (1.13 - 6.22)	0.02*	0.31 (0.12 - 0.80)	0.01*
Diarrhea	No	1		1	
	Yes	1.04 (0.14 - 7.44)	0.97	0.37 (0.04 - 3.64)	0.39
Headache	No	1		1	
	Yes	3.36 (1.52 - 7.40)	0.002*	0.45 (0.18 - 1.11)	0.08
Severe fatigue	No	1		1	
	Yes	3.09 (1.49 - 6.42)	0.002*	0.19 (0.09 - 0.41)	< 0.0001*
Irritability/Confusion	No	1		1	
	Yes	2.11 (0.52 - 8.58)	0.29	0.23 (0.06 - 0.98)	0.04*
Ageusia	No	1		1	
	Yes	11.62 (2.67 - 50.56)	0.001*	0.12 (0.05 - 0.29)	< 0.0001*
Anosmia	No	1		1	
	Yes	5.18 (1.46 - 18.38)	0.01*	0.15 (0.05 - 0.42)	0.0003*
Loss of appetite	No	1		1	
	Yes	-	-	0.08 (0.01 - 0.48)	0.005*

278 95%CI: Confidence interval at 95%, cOR: Crude odds ratio, aOR: Adjusted odds ratio, Ig:

279 Immunoglobulin, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

280 Univariate logistic regression analysis was performed to quantify the association between presence
281 of anti-SARS-CoV-2 antibodies (IgG and IgM) and clinical signs/symptoms

282 *Statistically significant at p -value < 0.05

283

284

285 **Predictors of anti-SARS-CoV-2 antibody response among**
 286 **unvaccinated patients**

287 The predictors of the presence of IgM antibodies included age and ageusia, while health
 288 facilities and ageusia were predictors of the presence of IgG antibodies (Table 4 and S7
 289 Table). The risk of being positive for IgM was reduced by 46% in patients aged 60 – 70 years
 290 (aOR = 0.54, 95%CI 0.18 – 0.87, $p = 0.02$). In contrast, the odds of IgM seropositivity were
 291 increased in patients diagnosed with ageusia (aOR = 9.31, 95%CI 1.49 – 58.08, $p = 0.01$).

292 **Table 4. Predictors of the presence of anti-SARS-CoV-2 antibodies among COVID-19**
 293 **unvaccinated patients.**

Predictors	IgM		IgG	
	aOR (95%CI)	p	aOR (95%CI)	p
Health facility, Deido	-	-	0.23 (0.06 - 0.83)	0.02*
Aged 60 - 70 years	0.54 (0.18 - 0.87)	0.02*	-	-
Ageusia	9.31 (1.49 - 58.08)	0.01*	0.21 (0.04 - 0.98)	0.04*

294 95%CI: Confidence interval at 95%, COVID-19: Coronavirus disease 2019, aOR: Adjusted odds ratio,

295 aOR: Adjusted odds ratio, Ig: Immunoglobulin

296 Multivariate logistic regression analysis was performed to identify the predictors of the presence of
 297 anti-SARS-CoV-2 antibodies (IgG and IgM)

298 *Statistically significant at p -value < 0.05

299

300

301 **Variation of the SARS–CoV–2 immune response among** 302 **unvaccinated patients**

303 The variations in mean levels of CD4+ cells, IFN- γ , and IL-6 by seropositivity status are
304 depicted in Figure 5. No significant variation was noted for CD4+ between IgM+ patients and
305 IgM- patients ($p = 0.11$). In contrast, increased levels have been observed in IFN- γ ($p = 0.01$)
306 and IL-6 ($p = 0.04$) in IgM+ patients compared to their IgM- counterparts. Regarding IgG
307 status, the levels of CD4+ cells were significantly higher in IgG+ patients ($p = 0.0048$), but an
308 inverted relation was found for IL-6 ($p = 0.0001$). The levels of IFN- γ were similar between
309 IgG+ patients and IgG- patients ($p = 0.87$) (Fig 5).

310 The impact of patients' characteristics (i.e., sociodemographic, anthropometric, and clinical
311 information) on the relation between seropositivity status, and CD4+ cells, IFN- γ , or IL-6 was
312 analysed (Fig 6). For instance, we compared the mean values of CD4+ cells, IFN- γ , and IL-6 of
313 IgM+ females with those of IgM- females, and the same comparisons were done for males.
314 Overall, the relationship between CD4+ cells and IgM or IgG status was not influenced by
315 patients' characteristics, with the exception of symptomatology and diabetes. The mean
316 levels of CD4+ were significantly reduced in IgM+ symptomatic patients compared to IgM-
317 symptomatic patients ($p = 0.01$), but the difference was no longer significant between IgM+
318 asymptomatic patients and IgM- asymptomatic patients ($p = 0.16$). Likewise, the same
319 pattern was noted upon stratification of the patients by diabetic status, with a significant
320 difference in CD4+ cells in diabetic patients ($p = 0.01$) but no longer in non-diabetic patients
321 ($p = 0.20$). CD4+ cells were significantly higher in IgM+ non-diabetic compared to IgM+ non-
322 diabetic ($p = 0.005$), but not in diabetic patients ($p = 0.56$). The association between
323 seropositivity status and IFN- γ or IL-6 was also modified by the patient's details (Fig 6).

324 **Fig 5. Overall variation of CD4+ (a, d), IFN- γ (b, e) and IL-6 (c, f) with respect to presence of**
325 **anti-SARS-CoV-2 IgM and IgG antibodies.** Ig: Immunoglobulin, IL-6: Interleukin 6, IFN- γ :
326 Interferon gamma, CD: Cluster of differentiation. The parametric unpaired sample Student's
327 t-test, and non-parametric Mann-Whitney test were used to compare the groups. *Statistically
328 significant at p -value < 0.05

329

330 **Fig 6. Variation of CD4+, INF- γ and IL-6 by seropositivity status, demographic, clinical, and**
331 **comorbidity information.** Ig: Immunoglobulin, SARS-CoV-2: Severe acute respiratory
332 syndrome coronavirus 2, IL-6: Interleukin 6, IFN- γ : Interferon gamma, CD: Cluster of
333 differentiation. The number of participants in each group are presented in round brackets.
334 The non-parametric unpaired sample Student's t-test was used to compare the groups.
335 *Statistically significant at p -value < 0.05

336

337 Discussion

338 The epidemiological situation of SARS-CoV-2 infection is still elusive in Cameroon, and this is
339 mainly due to a lack of testing campaigns in community. Molecular methods are the gold
340 standard for SARS-CoV-2 testing in populations. In developing countries, their
341 implementation at a large scale is strongly hindered by the high cost of these methods,
342 which are limited to a few research institutes and health facilities for research and small-
343 scale diagnosis purposes. Antibody-based assays constitute an interesting alternative to
344 molecular methods, especially for the rapid determination of the circulation of SARS-CoV-2.
345 This study aimed at determining the seroprevalence and determinants of SARS-CoV-2
346 antibodies among patients attending major health facilities for the management of COVID-
347 19 in Douala, Cameroon.

348 The overall seroprevalence of SARS-CoV-2 was 96.9%, which is consistent with those
349 reported in other settings such as Chile (97.3%) [10]. In contrast, lower seroprevalence
350 values were recently reported in Portugal (2.7 – 3.9%), Mozambique (3%), Bosnia and
351 Herzegovina (3.77%), Japan (3.9%), Denmark (5.3%), Chile (7.2%), Spain (9.6 - 21.9%), Italia
352 (11%), Sweden (11.8%), Iran (14%), Pakistan (16%), Iran (17.1%), Iraq (23.72%), Poland
353 (42.7%), USA (5.6 – 57.7%), and Lebanon (58.9%) [4,11,20–27,12–19]. Differences in study
354 period, SARS-CoV-2 variants, age groups, and COVID-19 vaccine coverage could explain
355 discrepancies between seroprevalence estimates. Also, we found higher seroprevalence
356 against IgM compared to IgG. This is not in line with reports from Iraq, where authors found
357 higher seroprevalence against IgG [4]. We noted that a high proportion of seropositive
358 patients were asymptomatic, and this could indicate that patients could control the SARS-
359 CoV-2 infection. A study found cross-reactive antibodies to SARS-CoV-2 were in circulation
360 among HIV patients before the COVID-19 pandemics [28], thereby suggesting the presence
361 of pre-existing anti-SARS-CoV-2- immunity that could contribute to attenuating disease
362 severity.

363 The presence of IgM antibodies to SARS-CoV-2 is a good proxy for recent infection, as they
364 are produced early in the antiviral humoral immune response. Nearly half of unvaccinated
365 patients were IgM positive, thereby suggesting a high circulation of SARS-CoV-2 among the
366 patients, and a need for adequate control measures, especially for those manifesting COVID-
367 19-related symptoms. This is the first seroprevalence study to report SARS-CoV-2 risk in
368 adults in Douala, the main populous and heterogeneous town of Cameroon. Before our
369 study, IgM seroprevalence estimates were available from studies conducted among health
370 care workers and the general population in the town of Yaoundé [29–31].

371 The prevalence of IgG was 88.9% in this study. Such a high prevalence estimate was also
372 reported in Cameroon by Ndongo Ateba *et al.* in Yaounde (18.6% to 51.3%) [32], Mansuy *et*
373 *al.* in pregnant women from Yaoundé (77%) [33], Njuwa Fai *et al.* in a community-based
374 study from Yaoundé (24%) [31], Deutou Wondeu *et al.* among university staff and students
375 (71.3%) in Bandjoun, a kingdom in the West Region of Cameroon [34], Sandie *et al.* among
376 blood donors from Douala and Yaoundé (66.3% to 98.4%) [35], and Diallo *et al.* among
377 unvaccinated individuals (74.8%) after the Omicron wave [36]. Lower values were reported
378 among dental teams in Germany (5.2%) [37] and young adults in Sweden (22.4%) [25]. The
379 chances of detecting anti-SARS-CoV-2 IgG were decreased by 77% in patients attending the
380 Deido district hospital compared to those attending the Bangue district hospital. This finding
381 could be explained by geographical differences in the risk of infection, which have also been
382 reported in previous studies [11].

383 Patients aged 60 – 70 years were less at risk of IgM seropositivity, which is consistent with
384 earlier studies [14,19,22,36,38,39]. In Bosnia and Herzegovina, Prguda-Mujic and colleagues
385 reported a reduced risk of positive anti-SARS CoV-2 Ig levels in patients aged over 50 years
386 old [19]. Other studies reported a reduced risk of SARS-CoV-2 positivity in younger
387 individuals [21,40]. This could be due to the fact that elderly individuals are more aware of
388 risks of COVID-19, and thus preventive methods could be more effectively implemented in
389 them [41]. This fact could also explain the reduced risk of anti-SARS CoV-2 IgG levels among
390 asthmatic patients found in the present study.

391 In this study, clinical symptoms were significantly associated with a higher risk of IgM
392 seropositivity, especially anosmia and ageusia. In addition, ageusia was the strongest
393 predictor of IgM seropositivity among the patients. Several studies across COVID-19 burden

394 varying settings also reported the clinical utility of COVID-19 evocating clinical symptoms, or
395 more specifically, fever, anosmia, and ageusia [20,22,23,25,26,40,42]. Ferreira *et al.* recently
396 reported that anosmia/dysgeusia was the most clinically discriminant symptoms in
397 Portuguese municipal workers, with a PPV and specificity of 52.2% and 99.3%, respectively.
398 Likewise, we found high estimates for anosmia (PPV = 82.4%, Sp = 98.3%) and for ageusia
399 (PPV = 90.9%, Sp = 98.9%) in this study. The pathophysiological mechanism of anosmia and
400 ageusia in COVID-19 is not yet fully understood, but studies have outlined that SARS-CoV-2
401 could elicit these olfactory and gustatory dysregulations either directly by infecting central
402 nervous system and gustatory/olfactory epithelium cells, or indirectly through the
403 production of cytokines such as tumour necrosis factor that may provoke the apoptosis of
404 nervous cells [43,44].

405 In line with previous studies, the levels of IFN- γ and CD4+ cells were decreased in
406 seropositive patients. Several studies outlined a delayed, decreased, or inhibited IFN- γ -
407 mediated immune response in SARS-CoV-2 and other related coronaviruses (e.g., SARS-
408 CoV-1). This dysregulation of the IFN- γ -mediated immune response is positively correlated
409 with the severity of COVID-19 [45,46]. The pathophysiological mechanism through which
410 SARS-CoV-2 provokes a dysregulation of the IFN- γ -mediated immune response included a
411 production of antagonists that act by downregulating signalling pathways and/or inhibiting
412 transcription factors [45,46]. Regarding CD4+ lymphocytes, they play a crucial role in the
413 immune response against SARS-CoV-2 [47-49]. COVID-19 patients generally present a
414 lymphopenia. Some authors suggested that the surveillance of lymphocyte subsets could be
415 helpful for improved diagnosis and treatment of COVID-19 patients [50]. To be noted, the
416 association between antibody seropositivity and CD4+, IFN- γ or IL-6 was modulated by
417 patients' characteristics. Such modulating impact have been previously reported for immune

418 response immune in India [51], and haematological biomarkers of COVID-19 in Cameroon
419 and India [52,53]. This is not surprising as these characteristics are well known to be
420 predictors of SARS-CoV-2 infection, severity, or deaths [54–56].

421 The findings from the present study should be interpreted in light of its limitations. First, the
422 study was conducted in seven health facilities in the town of Douala, thereby limiting its
423 generalisability at national level. Second, the study did not capture all environmental,
424 behavioural, and socio-demographic characteristics of patients (e.g., size of household,
425 socio-economic status) that could have impacted the risk of SARS-CoV-2 seropositivity
426 [21,23,42,57–59]. Third, the small number of patients with comorbidities such as heart
427 failure limited stratification analyses to identify possible confounding variables. Finally, the
428 antigens in the ELISA kits used were designed to target the original SARS-CoV-2 lineage that
429 emerged in China. Several variants of the virus, such as the Omicron or delta lineages, have
430 been reported in Cameroon during pandemic waves [60–62], and thus, it is likely that a few
431 infection cases were missed as these antigens may not optimally detect antibodies against
432 SARS-CoV-2 variants and that the seroprevalence is underestimated.

433 **Conclusions**

434 In this study, we aimed at determining seroprevalence, determinants of SARS-CoV-2
435 infection, and immunological alterations among unvaccinated patients living in Douala,
436 Cameroon. The findings indicate a high circulation of the virus among participants, with
437 several predictors of seropositivity including advanced age, health facility, and ageusia. In
438 general, immune response effectors (CD4+, IFN- γ , and IL-6) analysed in the study were
439 altered in seropositive individuals, with a confounding role of socio-demographic factors or
440 comorbidities. Although the WHO recently declared the end of COVID-19 as a global health

441 emergency, the findings of the present study indicate the need for continuous surveillance
442 to adequately control the disease in Cameroon.

443 **Abbreviations**

444 95%CI: Confidence interval at 95%, ALFA: Enzyme-linked immunofluorescent assay, ANOVA:
445 Analysis of variance, aOR: Adjusted odds ratio, cOR: Crude odds ratio, aRR: Adjusted risk
446 ratio, BMI: Body mass index, CD: Cluster of differentiation, cRR: Crude risk ratio, COVID-19:
447 Coronavirus disease 2019, df: Degree of freedom, ELISA: Enzyme-linked immunosorbent
448 assay, IFN: Interferon, Ig: Immunoglobulin, HIV: Human immunodeficiency virus, PPV:
449 Positive predictive value, ROC: Receiver operating curve, RT-qPCR: Retrotranscriptase
450 quantitative polymerase chain reaction, SARS-CoV-2: Severe acute respiratory syndrome
451 coronavirus 2, SD: Standard deviation, SE: Standard error, Sp: Specificity

452 **Acknowledgments**

453 The authors are grateful to patients having accepted to participate in the study. We also
454 acknowledge support and technical assistance of managing authorities, medical doctors and
455 staff of health facilities. We also acknowledge the assistance of Mr. Stephane Koum
456 (Department of Earth Sciences, The University of Douala, Cameroon) for generating maps.

457 **Author Contributions**

458 **Conceptualization:** Arlette Flore Moguem Soubgui, Martin Luther Koanga Mogtomo.

459 **Data curation:** Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Loick Pradel
460 Kojom Foko, Elisee Libert Embolo Enyegue.

461 **Formal analysis:** Arlette Flore Moguem Soubgui, Loick Pradel Kojom Foko, Martin Luther
462 Koanga Mogtomo.

463 **Investigation:** Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Elisee Libert
464 Embolo Enyegue, Martin Luther Koanga Mogtomo.

465 **Methodology:** Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Loick Pradel
466 Kojom Foko, Elisee Libert Embolo Enyegue, Martin Luther Koanga Mogtomo.

467 **Resources:** Arlette Flore Moguem Soubgui, Martin Luther Koanga Mogtomo.

468 **Project administration:** Martin Luther Koanga Mogtomo.

469 **Software:** Loick Pradel Kojom Foko.

470 **Supervision:** Martin Luther Koanga Mogtomo.

471 **Validation:** Loick Pradel Kojom Foko, Martin Luther Koanga Mogtomo.

472 **Writing – original draft:** Arlette Flore Moguem Soubgui, Loick Pradel Kojom Foko.

473 **Writing – review & editing:** Loick Pradel Kojom Foko, Martin Luther Koanga Mogtomo.

474 **Data availability statement**

475 All data are within the manuscript and supporting files, and relevant data underlying the
476 results presented in the study has been filed in the Dryad repository and available from
477 <https://doi.org/10.5061/dryad.1vhhmgr00>.

478 **Funding**

479 The author(s) received no specific funding for this work.

480 **Competing interests**

481 The authors have declared that no competing interests exist.

482 **References**

- 483 1. Kojom LP, Singh V. A review on emerging infectious diseases prioritized under the
484 2018 WHO Research and Development Blueprint: Lessons from the Indian context.
485 *Vector Borne Zoonotic Dis.* 2021;21(3):149–59.
- 486 2. Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural
487 history of COVID-19 and therapeutic options. *Expert Rev Clin Immunol.*
488 2020;16(12):1159–84. Available from:
489 <https://doi.org/10.1080/1744666X.2021.1847640>
- 490 3. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P,
491 Campo R Del, Ciapponi A, et al. False-negative results of initial RT-PCR assays for
492 COVID-19: A systematic review. *PLoS One.* 2020;15(12):e0242958.
- 493 4. Saeed AY, Assafi MS, Othman HE, Shukri HM. Prevalence of SARS -CoV-2 IgG/IgM
494 antibodies among patients in Zakho City, Kurdistan, Iraq. *J Infect Dev Ctries.*
495 2022;16(7):1126–30.
- 496 5. Mallano A, Ascione A, Flego M. Antibody response against SARS-CoV-2 infection:
497 Implications for diagnosis, treatment and vaccine development. *Int Rev Immunol.*
498 2022;41(4):393–413. Available from:
499 <https://doi.org/10.1080/08830185.2021.1929205>
- 500 6. Zhou W, Xu X, Chang Z, Wang H, Zhong X, Tong X, et al. The dynamic changes of serum

- 501 IgM and IgG against SARS-CoV-2 in patients with COVID-19. *J Med Virol.*
502 2021;93(2):924–33.
- 503 7. Kojom Foko LP, Nolla NP, Nyabeyeu Nyabeyeu H, Lehman LG. Prevalence, patterns,
504 and determinants of malaria and malnutrition in Douala , Cameroon : A cross-
505 sectional community-based study. *Biomed Res Int.* 2021;2021:5553344.
- 506 8. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence
507 of SARS-CoV-2 antibodies: A systematic review and metaanalysis. *PLoS One.*
508 2021;16:e0252617. Available from: <http://dx.doi.org/10.1371/journal.pone.0252617>
- 509 9. Lang TA, Altman DG. Basic statistical reporting for articles published in Biomedical
510 Journals: The “Statistical analyses and methods in the published literature” or the
511 SAMPL guidelines. *Int J Nurs Stud.* 2015;52(1):5–9. Available from:
512 <http://dx.doi.org/10.1016/j.ijnurstu.2014.09.006>
- 513 10. Aguilera X, González C, Apablaza M, Rubilar P, Icaza G, Ramírez-Santana M, et al.
514 Immunization and SARS-CoV-2 antibody seroprevalence in a country with high
515 vaccination coverage: Lessons from Chile. *Vaccines.* 2022;10(7):1002.
- 516 11. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared
517 A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk
518 occupational groups across 18 cities in Iran: a population-based cross-sectional study
519 Hossein. *Lancet Infect Dis.* 2021;21:473–81.
- 520 12. Arnaldo P, Mabunda N, Young PW, Tran T, Siteo N, Chelene I, et al. Prevalence of
521 SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic
522 study in three cities, July-August 2020. *Clin Infect Dis.* 2022;75(S2):S285–93.

- 523 13. Bahlwan O, Badra R, Semaan H, Fayad N, Kamel MN, El Taweel AN, et al. Prevalence
524 and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon. *Arch Virol.*
525 2022;167(7):1509–19. Available from: <https://doi.org/10.1007/s00705-022-05470-2>
- 526 14. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of
527 infection-induced SARS-CoV-2 antibodies-United States, September 2021-February
528 2022. *Morb Mortal Wkly Rep.* 2022;71(17):606–8. Available from:
529 <https://www.medrxiv.org/content/10.1101/2022.04.18.22271936v1?rss>
- 530 15. Goss CW, Maricque BB, Anwuri V V, Cohen RE, Donaldson K, Johnson KJ, et al. SARS-
531 CoV-2 active infection prevalence and seroprevalence in the adult population of St.
532 Louis County. *Ann Epidemiol.* 2022;71:31–7.
- 533 16. Johannesen CK, Martin GS, Lendorf ME, Garred P, Fyfe A, Paton RS, et al. Prevalence
534 and duration of anti-SARS-CoV-2 antibodies in healthcare workers. *Dan Med J.*
535 2022;69(5):A11210843.
- 536 17. Moreno S, Miró Q, Soler A, Gallego M, Homs M, Garcia MJ. Prevalence of SARS-CoV-2
537 antibodies and risk factors in the pandemic epicentre of Catalonia. *Sci Rep.*
538 2022;12(1):9169. Available from: <https://doi.org/10.1038/s41598-022-13290-2>
- 539 18. Mori Y, Tanaka M, Kozai H, Hotta K, Aoyama Y, Shigeno Y, et al. Prevalence of SARS-
540 CoV-2 antibodies among university athletic club members: A cross-sectional survey.
541 *Drug Discov Ther.* 2022;16(4):185–90.
- 542 19. Prguda-Mujic J, Hasanovic O, Besic L, Asic A, Halilovic S, Cestic AK, et al. Antibody
543 seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and
544 Herzegovina-One year later. *PLoS One.* 2022;17(3):e0265431. Available from:

- 545 <http://dx.doi.org/10.1371/journal.pone.0265431>
- 546 20. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of
547 antibodies to SARS-CoV-2 in Italian adults and associated risk factors. *J Clin Med*.
548 2020;9(9):2780.
- 549 21. Żółtowska B, Barańska I, Jachowicz E, Sydor W, Maziarz B, Mydel K, et al. The
550 seroprevalence of SARS-CoV-2 antibodies among healthcare workers in university
551 hospital in Krakow before the era of vaccination. *Int J Environ Res Public Health*.
552 2022;19(7):4044.
- 553 22. Zuñiga M, Lagomarcino AJ, Muñoz S, Peña A, Andrea M, O’Ryan ML. A cross sectional
554 study found differential risks for COVID-19 seropositivity amongst health care
555 professionals in Chile. *J Clin Epidemiol*. 2022;144:72–83.
- 556 23. Javed W, Abidi SHB, Baqar J Bin. Seroprevalence and characteristics of Coronavirus
557 Disease (COVID-19) in workers with non-specific disease symptoms. *BMC Infect Dis*.
558 2022;22:481. Available from: <https://doi.org/10.1186/s12879-022-07461-9>
- 559 24. Arabkhazaeli A, Maghsudlu M, Mohammadi S, Eshghi P. Positive anti-SARS-CoV-2
560 rapid serological test results among asymptomatic blood donors. *Transfus Clin Biol*.
561 2022;29(1):24–30.
- 562 25. Bjorkander S, Du LI, Zuo F, Ekstrom S, Wang Y, Wan H, et al. SARS-CoV-2–specific B-
563 and T-cell immunity in a population-based study of young Swedish adults. *J Allergy
564 Clin Immunol*. 2022;149(1):65–75.
- 565 26. Ferreira NB, Pereira H, Pereira AM, Azevedo LF, Santos M, Maranhão P, et al.
566 Seroprevalence of SARS-CoV-2 and assesment of epidemiological determinants in

- 567 Portugese municipal workers. *Int J Occup Med Environ Health*. 2022;35(3):297–307.
- 568 27. Martínez CA, Pastor JCS, Sánchez IMM, Giménez AN, de Antón MG, Chacón PA.
569 Prevalence of SARS-CoV-2 infection during the first wave of the pandemic among
570 health and non-health personnel of the General Hospital of Segovia, Castilla y León.
571 *Rev Esp Quimioter*. 2022;35(2):157–64.
- 572 28. Aissatou A, Fokam J, Semengue ENJ, Takou D, Ka'e AC, Ambe CC, et al. Pre-existing
573 immunity to SARS-CoV-2 before the COVID-19 pandemic era in Cameroon: A
574 comparative analysis according to HIV-status. *Front Immunol*. 2023;14:1155855.
- 575 29. Nwosu K, Fokam J, Wanda F, Mama L, Orel E, Ray N, et al. SARS-CoV-2 antibody
576 seroprevalence and associated risk factors in an urban district in Cameroon. *Nat*
577 *Commun*. 2021;12:5851.
- 578 30. Nguwoh PS, Mboringong AB, Fokam J, Ngounouh Taheu C, Halilou I, Djieudeu Nouwe
579 SH, et al. Seroprevalence of SARS-CoV-2 (COVID-19) among health care workers in
580 three health facilities of Yaounde, Center Region of Cameroon. *Eur J Med Health Sci*.
581 2021;3(6):89–94.
- 582 31. Fai KN, Corine TM, Bebell LM, Mboringong AB, Nguimbis EBPT, Nsaibirni R, et al.
583 Serologic response to SARS-CoV-2 in an African population. *Sci African*.
584 2021;12:e00802. Available from: <https://doi.org/10.1016/j.sciaf.2021.e00802>
- 585 32. Ndongo Ateba F, Guichet E, Mimbé ED, Ndié J, Pelloquin R, Varloteaux M, et al. Rapid
586 increase of community SARS-CoV-2 seroprevalence during second wave of COVID-19,
587 Yaoundé, Cameroon. *Emerg Infect Dis*. 2022;28(6):1233–6.
- 588 33. Mansuy JM, Kenfack M, Burel S, Bidzogo Lebobo M, Ekae C, Berry A, et al. High SARS-

- 589 CoV-2 IgG seroprevalence among pregnant Cameroun women 14 months after the
590 beginning of the pandemic. *Public Health*. 2022;S0033-3506(22)00260-8.
- 591 34. Deutou Wondeu AL, Talom BM, Linardos G, Ngoumo BT, Bello A, Soufo AMN, et al.
592 The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies
593 among staff and students in a Cameroon University. *J Public Health Africa*.
594 2023;14(1):2242.
- 595 35. Sandie AB, Ngo Sack F, Medi Sike CI, Mendimi Nkodo J, Ngegni H, Ateba Mimfoumou
596 HG, et al. Spread of SARS-CoV-2 infection in adult populations in Cameroon: A
597 repeated cross-sectional study among blood donors in the cities of Yaoundé and
598 Douala. *J Epidemiol Glob Health*. 2023;13(2):266–78. Available from:
599 <https://doi.org/10.1007/s44197-023-00102-7>
- 600 36. Diallo MSK, Amougou-Atsama M, Ayouba A, Kpamou C, Mimbe Taze ED, Thaurignac G,
601 et al. Large diffusion of severe acute respiratory syndrome coronavirus 2 after the
602 successive epidemiological waves, including Omicron, in Guinea and Cameroon:
603 Implications for Vaccine Strategies. *Open Forum Infect Dis*. 2023;10(5):ofad216.
604 Available from: <https://doi.org/10.1093/ofid/ofad216>
- 605 37. Mksoud M, Ittermann T, Holtfreter B, Söhnel A, Söhnel C, Welk A, et al. Prevalence of
606 SARS-CoV-2 IgG antibodies among dental teams in Germany. *Clin Oral Investig*
607 [Internet]. 2022;26(5):3965–74. Available from: [https://doi.org/10.1007/s00784-021-](https://doi.org/10.1007/s00784-021-04363-z)
608 [04363-z](https://doi.org/10.1007/s00784-021-04363-z)
- 609 38. Chang L, Hou W, Zhao L, Zhang Y, Wang Y, Wu L, et al. The prevalence of antibodies to
610 SARS-CoV-2 among blood donors in China. *Nat Commun*. 2021;12:1383.

- 611 39. Fogh K, Eriksen ARR, Hasselbalch RB, Kristensen ES, Bundgaard H, Nielsen SD, et al.
612 Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark. *BMC*
613 *Infect Dis.* 2022;22:143. Available from: <https://doi.org/10.1186/s12879-022-07102-1>
- 614 40. Hansen CB, Dvoncova K, Pérez-Alós L, Fogh K, Madsen JR, Garred CH, et al. SARS-CoV-
615 2 antibody dynamics over time and risk factors associated with infection and long
616 COVID-19 symptoms in large working environments. *J Intern Med.* 2023;293(6):763–
617 81.
- 618 41. Lu P, Kong D, Shelley M. Risk perception, preventive behavior, and medical care
619 avoidance among American older adults during the COVID-19 pandemic. *J Aging*
620 *Health.* 2021;33(7–8):577–84.
- 621 42. Montaña-Castellón I, Lins-Kusterer L, Luz E, Pedroso C, Paz M, Brites C. SARS-CoV-2
622 incidence, signs and symptoms and main risk factors for COVID-19 infection in health
623 care workers: A hospital-wide survey in Salvador, Brazil. *Brazilian J Infect Dis.*
624 2022;26(4):102387.
- 625 43. Shamsundara M, Jayalakshmi L. Anosmia—An effect of COVID-19 infection-review.
626 *Indian J Otolaryngol Head Neck Surg.* 2023;75:S815–21. Available from:
627 <https://doi.org/10.1007/s12070-022-03401-w>
- 628 44. Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H, SeyedAlinaghi SA. Olfactory
629 and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of
630 current evidence. *Eur Arch Oto-Rhino-Laryngology.* 2021;278(2):307–12. Available
631 from: <https://doi.org/10.1007/s00405-020-06120-6>
- 632 45. Schenten D, Bhattacharya D. Immunology of SARS-CoV-2 infections and vaccines. *Adv*

- 633 Immunol. 2021;151:49–97.
- 634 46. Tian Y, Carpp LN, Miller HE, Zager M, Newell EW, Gottardo R. Singular insights into the
635 immunology of SARS-CoV-2 infection. *Nat Biotechnol.* 2022;40(1):30–41.
- 636 47. DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following
637 natural infection and vaccination. *Biochem Biophys Res Commun.* 2021;538:211–7.
- 638 48. Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology,
639 vaccines, variants, and therapeutics. *Curr Med Sci.* 2021;41(6):1037–51.
- 640 49. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell.*
641 2021;184:861–80.
- 642 50. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in
643 patients with COVID-19 in Wuhan, China Chuan. *Clin Infect Dis.* 2020;71(15):762–8.
- 644 51. Singh M, Barrera Adame O, Nickas M, Robison J, Khatchadourian C, Venketaraman V.
645 Type 2 diabetes contributes to altered adaptive immune responses and vascular
646 inflammation in patients with SARS-CoV-2 infection. *Front Immunol.* 2022;13:833355.
- 647 52. Mogueu Soubgui AF, Kojom Foko LP, Embolo Enyegue EL, Ndeme Mboussi WS, Mbebi
648 Enone JP, Ntatu Lemouchele I, et al. Confounding role of comorbidities and COVID–
649 19 vaccination uptake in clinical utility of hematological biomarkers in Cameroonian
650 patients infected with SARS–CoV–2. *IJID.* 2023;Ahead of Print.
- 651 53. Parthasarathi A, Basavaraja CK, Arunachala S, Chandran S, Venkataraman H, Satheesh
652 A, et al. Comorbidities influence the predictive power of hematological markers for
653 mortality in hospitalized COVID-19 patients. *Adv Respir Med.* 2022;90(1):49–59.

- 654 54. Centers for Disease Control and Prevention. People who are at higher risk for severe
655 illness | CDC. *Centers Dis Control Prev.* 2020;68:703–10. Available from:
656 [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html)
657 [higher-risk.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html)
- 658 55. Moguem Soubgui AF, Embolo Enyegue EL, Kojom Foko LP, Ndeme Mboussi WS,
659 Deutou Hogoue G, Mbougang SP, et al. Epidemiological situation of SARS-CoV-2
660 infection in Douala, the most populated and highly heterogeneous town of Cameroon:
661 a post-vaccination update. *Acta Trop.* 2023;241:106864. Available from:
662 <https://doi.org/10.1016/j.actatropica.2023.106864>
- 663 56. Ebongue MSN, Lemogoum D, Endale-Mangamba LM, Barche B, Eyoum C, Simo Yomi
664 SH, et al. Factors predicting in-hospital all-cause mortality in COVID 19 patients at the
665 Laquintinie Hospital Douala, Cameroon. *Travel Med Infect Dis.* 2022;47:102292.
666 Available from: <https://doi.org/10.1016/j.tmaid.2022>
- 667 57. Mercado-Reyes MM, Daza M, Pacheco A, Meneses-Gil MX, Galindo M, Catama J, et al.
668 Seroprevalence of SARS-CoV-2 antibodies in children and adolescents: Results from a
669 population-based survey in 10 Colombian cities. *Glob Pediatr Heal.* 2022;9:1–16.
- 670 58. Talaei M, Faustini S, Holt H, Jolliffe DA, Vivaldi G, Greenig M, et al. Determinants of
671 pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal
672 study (COVIDENCE UK). *BMC Med.* 2022;20:87. Available from:
673 <https://doi.org/10.1186/s12916-022-02286-4>
- 674 59. Rodríguez MF, Porrás-Villamil JF, Martín L V., Rivera JE, Mantilla YC, Olivera MJ.
675 Seroprevalence of IgM and IgG anti-SARS-COV-2 and associated factors among
676 agricultural workers in Colombia. *New Microbes New Infect.* 2022;48:101026.

677 Available from: <https://doi.org/10.1016/j.nmni.2022.101026>

678 60. Colson P, Delerce J, Burel E, Dahan J, Jouffret A, Fenollar F, et al. Emergence in
679 southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K
680 substitutions in the spike protein. *Arch Virol.* 2022;167(4):1185–90. Available from:
681 <https://doi.org/10.1007/s00705-022-05385-y>

682 61. Chouikha A, Lagare A, Ghedira K, Diallo A, Njouom R, Sankhe S, et al. SARS-CoV-2
683 lineage A.27: New data from African countries and dynamics in the context of the
684 COVID-19 pandemic. *Viruses.* 2022;14(5):1007.

685 62. Njouom R, Sadeuh-mba SA, Tchatchueng J, Dia N, Tagnouokam Ngoupo PA, Boum Y,
686 et al. Coding-complete genome sequence and phylogenetic relatedness of a SARS-
687 CoV-2 strain detected in March 2020 in Cameroon. *Microbiol Resour Announc.*
688 2020;3:e00093-21.

689

690

691

692

693

694

695

696

697 **Supporting information**

698 **S1 Fig. Ethical clearance of the study.**

699 **S2 Fig. Testing SARS-CoV-2 immune response parameters (IgM, IgG, CD4+, IFN- γ and IL-6)**
700 **and age for Gaussian distribution.**

701 **S3 Table. SARS-CoV-2 seroprevalence profile by health facilities.**

702 **S4 Table. SARS-CoV-2 seroprevalence profile by clinical symptoms.**

703 **S5 Table. Clinical value of symptoms for prognostic of IgG seropositivity.**

704 **S6 Table. Association between immune response and patients' characteristics among**
705 **COVID-19 unvaccinated patients.**

706 **S7 Table. Details of multivariate logistic regression analysis of the presence of anti-SARS-**
707 **CoV-2 IgM or IgG antibodies.**

708




Fig 1




Fig 2





Fig 3

Immunoglobulin M

Immunoglobulin G

Immunoglobulins G + M




Fig 4




Fig 5




Fig 6